DARE
Dare Bioscience Inc
NASDAQ · Pharmaceuticals
$1.69
+0.01 (+0.60%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 6.97M | 6.37M | 6.18M |
| Net Income | 1.03M | 1.14M | 939.3K |
| EPS | — | — | — |
| Profit Margin | 14.8% | 17.9% | 15.2% |
| Rev Growth | +17.6% | +7.5% | -4.9% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 9.38M | 9.41M | 9.16M |
| Total Equity | 13.47M | 13.13M | 13.27M |
| D/E Ratio | 0.70 | 0.72 | 0.69 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 1.81M | 1.58M | 1.73M |
| Free Cash Flow | 730.8K | 772.3K | 654.4K |